Plan for the sale, not the IPO

Two decades of biotech exits point in one direction: the large developers are buying earlier, and they are paying for de-risked science rather than finished products. Recent 2026 transactions make the pattern concrete. Lilly agreed to acquire Kelonia for about $3.25 billion up front and up to roughly $7 billion in total. Lilly bought Orna for about $2.4 billion. Bristol Myers Squibb agreed to take Orbital for about $1.5 billion around a preclinical CD19 autoimmune program. Johnson and Johnson agreed to acquire Sail for about $785 million up front, including roughly $465 million in equity, plus an option worth up to about $2.58 billion.

One widely shared analysis of the broader market, from Kjellgren at Kellbridge, counts dozens of acquisitions this cycle with a large share at the preclinical or Phase 1 stage, and a meaningful number of outright buyouts in the first half of 2026 alone. The common thread is that control changed hands before approval, often well before it.

For a founder, the practical implication is to plan for the sale, not only the IPO. Pharma tends to move earlier than inventors expect, and the owners who capture the most value are the ones who built the data package and the relationships before they needed them. By the time a company is forced to sell, its leverage is already gone. The better posture is to be ready to be bought while you still have the option not to.

Nothing here is investment advice, and this note is not an endorsement of any transaction described. Figures are as publicly reported.

Work with Modulus

Filling a pipeline gap?

Talk to us →

Have a program worth de-risking?

See how we work with inventors →